Project Grant R21AG098875
Award Date 2/15/26
Completion Date 1/31/28
Dollars Obligated $432K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
- Federal Project Grant Award Summary Rush University Medical Center received a $1,987,698 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) effective July 1, 2025, through April 30, 2030. The award funds research to identify molecular mechanisms linking cerebrovascular disease (CVD) pathologies to Alzheimer's disease and Alzheimer's disease and related dementias (AD/ADRD) in older adults. The research leverages existing clinical, pathological, and...
- Federal Project Grant Award Summary The University of Cincinnati's Sponsored Research Services Division received a $324,000 Project Grant award from the National Institute on Aging (Aging Research program, CFDA 93.866) effective February 15, 2026, through January 31, 2028. This award funds a comparative effectiveness research study utilizing real-world data to evaluate glucagon-like peptide-1 (GLP-1) agonists as a preventive treatment for Alzheimer's disease progression in patients with mild...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded The Johns Hopkins University a $622,086 project grant on May 15, 2025, under the Aging Research program (CFDA 93.866) to conduct research investigating microglial NOD2/RIPK2 (nucleotide-binding oligomerization domain-containing protein 2/receptor-interacting serine/threonine-protein kinase 2) signaling in Alzheimer's disease (AD) pathophysiology. The research project, with an anticipated completion date of February...
- Federal Project Grant Award Summary Lighthouse Pharmaceuticals, Inc. received a $37.78 million Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded August 15, 2025, with completion anticipated by July 31, 2029. The award funds a randomized, double-blind, placebo-controlled clinical trial investigating LHP588 (a next-generation gingipain inhibitor) in subjects with Porphyromonas gingivalis (P. gingivalis)-positive Alzheimer's disease....
- This $1,246,362 project grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to Rush University Medical Center aims to elucidate the morphology and compositional changes of the perivascular pia mater (PVS PIA) in the human brain across aging and Alzheimer's disease. The 3-year project will leverage clinical and pathological data from the Rush Religious Orders Study and Memory and Aging Project to map PVS PIA anatomy using advanced microscopy techniques. Key...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded J. David Gladstone Institutes a Project Grant totaling $804,450 (awarded June 1, 2025, with completion targeted for March 31, 2030) under the Aging Research program (CFDA 93.866) to conduct biomedical research investigating the molecular mechanisms underlying Apolipoprotein E4 (APOE4)-driven pathogenesis in Alzheimer's disease (AD). The research will focus on targeting the growth factor protein NELL2 (Neural...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded $127,224 to the University of California, San Diego on October 24, 2025, under the Aging Research program (CFDA 93.866) to support scientific investigation into the pathological mechanisms of Alzheimer's disease (AD). The project, which extends through August 31, 2028, will elucidate the role of s-nitrosylated phospholipase D3 (SNO-PLD3) in microglial and neuronal pathophysiology associated with AD. Specifically,...
- Federal Grant Award Summary New York University School of Medicine received a $3.104 million Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded September 15, 2025, with a completion date of May 31, 2030. The research initiative, titled "Peripheral Immunity and the Aging Brain: Studying the Relationship of Platelet and Neutrophil Activity with Markers of Vascular Contributions to Cognitive Decline and Dementia," delivers a...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded Massachusetts General Hospital a $1.58 million Project Grant on March 15, 2025, under the Aging Research program (CFDA 93.866) to conduct research characterizing microvascular impairment in adults with elevated genetic risk for Alzheimer's disease. The research initiative, which extends through January 31, 2030, investigates the physiological mechanisms through which the apolipoprotein E-epsilon 4 (APOE-E4) alleleā€”the...
- Federal Grant Award Summary Brigham & Women's Hospital Inc. received a $6.47 million R01 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866), awarded September 1, 2025, with completion scheduled for August 31, 2030. The grant funds the Ante-Amyloid Treatment of Alzheimer's Disease (A3) Trial and the Alzheimer Plasma Extension (APEX) Study, which are components of the AHEAD 3-45 clinical trial initiative. The A3 Trial is a Phase IIB prevention...